Molecular diagnostics and consumer testing company Imaware has acquired Binx Health’s at-home consumer testing business for an undisclosed sum.
According to a statement issued by the companies, the acquisition will expand Imaware’s test menu and its position in the growing home-health testing market, as well as broaden the number of enterprise clients Imaware serves.
Under the agreement, Binx Health will retain its POC molecular diagnostics business, which is excluded from the Imaware transaction.
Imaware offers home-based tests, including custom panels, for an array of conditions, including autoimmune, infectious, and allergic diseases. The Binx io platform has received approval from the U.S. Food and Drug Administration to detect chlamydia and gonorrhea in both vaginal swab specimens and male urine samples in about 30 minutes.
